Send to

Choose Destination
Biochem Biophys Res Commun. 2015 Jan 2;456(1):20-8. doi: 10.1016/j.bbrc.2014.11.024. Epub 2014 Nov 15.

Discovering novel direct acting antiviral agents for HBV using in silico screening.

Author information

Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan. Electronic address:
Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan.
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Department of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe 650-0017, Japan.
Department of Biological Science, Chuo University, Tokyo 112-8551, Japan.


The treatments for chronic hepatitis B (CHB) are interferon and nucleoside analogues reverse transcriptase (RT) inhibitors. Because both treatments are less than ideal, we conducted to identify novel anti-viral agents for HBV-reverse transcriptase (HBV-RT). We determined the ligand-binding site of the HBV-RT by conducting a homological search of the amino acid sequence and then we also determined not only structural arrangement of the target protein but the target protein-binding site of the ligand using known protein-ligand complexes in registered in the protein data bank (PDB). Finally we simulated binding between the ligand candidates and the HBV-RT and evaluated the degree of binding (in silico screening). PXB cells derived from human-mouse chimeric mouse liver, infected with HBV were administrated with the candidates, and HBVDNA in the culture medium was monitored by realtime qPCR. Among compounds from the AKosSamples database, twelve candidates that can inhibit RT were also identified, two of which seem to have the potential to control HBV replication in vitro.


Hepatitis B virus; In silico screening; Reverse transcriptase

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center